Sector movers: House builders and banks rally
8th Jul 2016 18:37
(ShareCast News) - House builders, banks topped the blue-chip winners' ladder at close of play on Friday, having last week and this suffered under the shadow of Britain's non-binding vote to quit the EU. Taylor Wimpey, Berkeley Group, Barratt Developments and Persimmon sprinted higher with gains of
Read moreAstraZeneca signs up to $1bn deal with LEO Pharma
1st Jul 2016 07:19
(ShareCast News) - Pharmaceutical giant AstraZeneca announced on Friday it has entered into agreements to support its strategic focus on three main therapy areas - respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and oncology. The FTSE 100 firm said the agreements in
Read moreAstrazeneca wins approval for new antibiotic in fight against drug resistance
28th Jun 2016 07:08
(ShareCast News) - AstraZeneca has won European regulatory approval for Zavicefta, a combination antibiotic developed in response to the increasingly urgent need for new drugs to treat serious infections that are becoming increasingly resistant to antibiotics. Zavicefta, a combination of ceftazidime
Read moreSunday share tips: EasyJet, Randgold, Imperial Brands, AstraZeneca
26th Jun 2016 14:03
(ShareCast News) - Sell EasyJet shares due to the likely turbulence sparked by the Brexit vote, said the Sunday Times' Inside the City column. The budget airline was created by Stelios Haji-Ioannou in the wake of the 1992 European Union Treaty on Open Skies, one of the supposedly rare bits of Brusse
Read moreUS authorities recommend against AstraZeneca flu vaccine
23rd Jun 2016 07:32
(ShareCast News) - Pharmaceutical giant AstraZeneca confirmed disappointing news to investors on Thursday, with updated guidance from US regulators recommending against its FluMist Quadrivalent influenza vaccine. The FTSE 100 firm said the updated guidance from the Advisory Committee on Immunization
Read moreLeave vote would have limited impact on FTSE, says SpreadCo analyst
21st Jun 2016 13:12
(ShareCast News) - Although consensus is that the FTSE 100 will rally if voters in the UK opt to remain in the European Union on Thursday and sell off on a Leave vote, the overall impact of an exit on London stocks may be limited, said SpreadCo analyst David Morrison. "The damage to the FTSE100 as a
Read moreBroker tips: Imperial Brands, Poundland, Astrazeneca
17th Jun 2016 12:06
(ShareCast News) - RBC Capital Markets upgraded Imperial Brands to 'sector perform' from 'underperform' and lifted the price target to 3,700p from 2,900p. The Canadian bank said Imperial's expected full-year 2017 dividend yield of 4.9% is the highest in its coverage and particularly attractive in th
Read moreHSBC reiterates 'hold' on Astrazeneca
17th Jun 2016 10:59
(ShareCast News) - HSBC reiterated a 'hold' rating on Astrazeneca after the US consumer watchdog increased its drug safety warning of the risk of acute kidney failure for the SGLT-2 inhibitors Farxiga and Invokana. The US Food and Drug Administration (FDA) has revised the warnings in the labels of t
Read moreThursday broker round-up
9th Jun 2016 16:34
(ShareCast News) - Fevertree Drinks: Berenberg upgrades to buy with a target price of 810p. AO World: JP Morgan keeps at neutral with a 200p target. WH Smith: JP Morgan stays at overweight with a target price of 1850p. Lancashire Holdings: UBS keeps at neutral with a target of 610p. Admiral Group
Read moreAstraZeneca in $770m deal with Aspen Group
9th Jun 2016 07:36
(ShareCast News) - AstraZeneca said it has entered a $770m commercialisation deal with Aspen Global Incorporated (AGI), part of the the US Aspen Group, for rights to its global anaesthetics portfolio outside the US. Under the terms of the agreement, AGI will acquire the commercialisation rights, out
Read moreAstraZeneca completes Zurampic deal with Ironwood
3rd Jun 2016 07:52
(ShareCast News) - Drugmaker AstraZeneca continued its charge of licensing its Zurampic (lesinurad) drug on Friday, with the company announcing it has completed its licensing agreement with Ironwood Pharmaceuticals for the exclusive United States rights to the drug. The FTSE 100 firm said the agreem
Read moreAstraZeneca signs major deal with Grunenthal over Zurampic
2nd Jun 2016 07:08
(ShareCast News) - Pharmaceutical and biologics company AstraZeneca announced on Thursday that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. The FTSE 100 firm received approval from the European Medicines
Read moreSunday newspaper round-up: AstraZeneca, oil IPOs, M&S, Exova, Tesco
29th May 2016 16:22
(ShareCast News) - AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous
Read moreAstraZeneca gets positive breast cancer trial results; potassium drug suffers setback
27th May 2016 07:32
(ShareCast News) - Phamaceuticals giant AstraZeneca announced positive results for its Faslodex drug for the treatment of metastatic breast cancer, but also said US regulators will not currently approve its new drug for high potassium levels because of a manufacturing issue. The company said on Frid
Read moreLondon pre-open: G7 warns of Brexit risks
27th May 2016 07:29
(ShareCast News) - Stocks are set for a slightly lower open as traders tread cautiously ahead of a speech by Fed chair Janet Yellen towards the close of trading in London and ahead of the release of key economic indicators Stateside. The fact that investors are heading into a long weekend on both si
Read more